Genentech Wants Other Firms' Compounds For Mass Pediatric Cancer Screening
Executive Summary
Master protocol for Phase I/II screening trial could make development more efficient, but concerns about regulatory obligations, lack of registrational intent and infrastructure complexity – as well as firms' willingness to share – may be hurdles to participation.
You may also be interested in...
Master Protocols In Practice
Basket trials are building a path for tissue-agnostic drug development in oncology, and plans are proceeding for more master protocols in pediatric cancers, acute myeloid leukemia and pancreatic cancer.
Pediatric Drug Development A Priority For US FDA’s New Oncology Center Of Excellence
Existing regulatory authorities could be optimized to speed development of promising pediatric cancer therapeutics, particularly those that don’t work in adult cancers.
AML Master Protocol For Precision Medicine Developed By Nonprofit And US FDA
Leukemia & Lymphoma Society worked with US FDA on umbrella trial strategy to accelerate development of new targeted therapies in molecularly-defined subsets of AML.